Headline News

 

AbbVie set to present phase 3 ECLIPSE data of Atogepant superiority in the acute treatment of migraines

Posted on January 06, 2026

GSK’s Nucala approved for use in adults with chronic obstructive pulmonary disease

Posted on January 06, 2026

Exdensur officially approved for severe asthma and chronic rhinosinusitis with nasal polyps in Japan

Posted on January 06, 2026

Astrazeneca’s Saphnelo self-administration TULIP-SC trial highlights meaningful reduction in systemic lupus erythematosus disease activity

Posted on January 06, 2026

Tzield accepted for priority review for young children with stage 2 type 1 diabetes

Posted on January 06, 2026

Johnson & Johnson phase 2b DUPLEX-AD study statement

Posted on December 30, 2025

TREMFYA approved for the treatment of children with plaque psoriasis

Posted on December 30, 2025

Johnson & Johnson completes acquisition of Halda Therapeutics

Posted on December 30, 2025

Abbott’s Volt pulsed field ablation system receives approval for the treatment of atrial fibrillation

Posted on December 30, 2025

Roche’s Lunsumio VELO approved for subcutaneous use in relapsed or refractory follicular lymphoma

Posted on December 30, 2025

Dupixent approved for children aged 6 to 11 years with bronchial asthma

Posted on December 30, 2025

Sanofi’s Wayrilz approved as the first BTK inhibitor to treat immune thrombocytopenia

Posted on December 30, 2025

Sanofi’s update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Posted on December 30, 2025

Sanofi set to acquire Dynavax to add marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to their pipeline

Posted on December 30, 2025

Thermo Fisher Scientific announces new launch of PPD CorEvitas Alzheimer’s disease registry to advance real-world evidence in neurodegenerative care

Posted on December 22, 2025